Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Current Assets (2021 - 2026)

Zentalis Pharmaceuticals has reported Current Assets over the past 6 years, most recently at $218.1 million for Q1 2026.

  • For Q1 2026, Current Assets fell 36.39% year-over-year to $218.1 million; the TTM value through Mar 2026 reached $218.1 million, down 36.39%, while the annual FY2025 figure was $253.2 million, 34.42% down from the prior year.
  • Current Assets for Q1 2026 was $218.1 million at Zentalis Pharmaceuticals, down from $253.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $563.9 million in Q2 2023 and troughed at $218.1 million in Q1 2026.
  • A 5-year average of $399.9 million and a median of $410.2 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: surged 36.16% in 2023 and later crashed 36.39% in 2026.
  • Year by year, Current Assets stood at $451.9 million in 2022, then increased by 9.91% to $496.7 million in 2023, then dropped by 22.28% to $386.1 million in 2024, then tumbled by 34.42% to $253.2 million in 2025, then fell by 13.86% to $218.1 million in 2026.
  • Business Quant data shows Current Assets for ZNTL at $218.1 million in Q1 2026, $253.2 million in Q4 2025, and $288.3 million in Q3 2025.